Morgan Stanley Analyst Initiates Equal Weight Rating On Personalis, Inc. (PSNL)

Personalis, Inc. (NASDAQ:PSNL) is among the 12 Best Genomics Stocks to Invest In.

The Fly reported on December 2, 2025, that Morgan Stanley analyst Kallum Titchmarsh took over coverage of Personalis, Inc. (NASDAQ:PSNL) with an Equal Weight rating and a price objective of $11, up from $9. The firm identified several upcoming catalysts within its coverage universe starting in 2026 and outlined growing bright spots across life science instruments and diagnostics end markets. Morgan Stanley claimed that a valuation surge in the second half of the year left industry multiples at fair levels despite favorable sector dynamics, prompting the bank to start coverage with an In-Line industry stance.

In addition, Personalis, Inc. (NASDAQ:PSNL) lowered its full-year 2025 sales forecast from $70 million to $80 million to a range of $68 million to $73 million. The projected income from pharmaceutical testing, services, and other clients has been reduced from $52 million to $58 million to $50 million to $54 million.

In contrast to previous projections of $15 million to $16 million, revenue from population sequencing and enterprise clients was raised to $16.5 million to $17 million. Clinical test reimbursed revenue has dropped from $3 million to $6 million to $1.5 million to $2 million. Gross margin estimate of 22% to 24%, net loss of about $85 million, and cash consumption of about $75 million were all reiterated by the business.

Personalis, Inc. (NASDAQ:PSNL) offers genomic sequencing and analytics technologies to help develop tailored cancer vaccines and other next-generation cancer immunotherapies.

While we acknowledge the potential of PSNL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025.

Disclosure. None